-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
NCT06298916 ·
Phase: Phase 1, Phase 2 ·
Ages: 15 Years and older ·
Sex: All (male and female) · 10 locations
-
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 27 locations
-
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
NCT06232083 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
NCT07578571 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 6 locations
-
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
NCT06500052 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 54 locations
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 39 locations
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 18 locations
-
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
NCT07390838 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 9 locations
-
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 14 locations
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 31 locations
-
AB122 Platform Study
NCT04999761 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 9 locations
-
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 9 locations
-
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
NCT03740256 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Brodalumab in the Treatment of Immune-Related Adverse Events
NCT06673329 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
NCT06006390 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 12 locations
-
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
NCT07179692 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 6 locations
-
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
NCT07410676 ·
Phase: Phase 1, Phase 2 ·
Ages: No age limits stated ·
Sex: All (male and female) · 1 location
-
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 117 locations
-
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT02584244 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
IDOV-Immune for Advanced Solid Tumors
NCT06910657 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 10 locations
-
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female) · 22 locations
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 17 locations
-
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 15 locations
-
SL-28 for Advanced Solid Tumours
NCT07341737 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 9 locations
-
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06047379 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 7 locations
-
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
NCT06532799 ·
Phase: Phase 1, Phase 2 ·
Ages: 16 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
NCT05187338 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 3 locations
-
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female) · 15 locations